tradmap

RXRX Earnings Recursion Pharmaceuticals, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing

Annual results

Diluted EPS (annual)
-$4 -$2 $0 2019 2020 2021 2022 2023 2024 2025
EPS
Revenue (annual)
$0 $37M $75M 2019 2020 2021 2022 2023 2024 2025
Revenue
Net income (annual)
-$645M -$322M $0 2019 2020 2021 2022 2023 2024 2025
Net income

Quarterly results

Diluted EPS (quarterly)
-$1 -$0 $0 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
EPS
Revenue (quarterly)
$0 $18M $36M Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
Revenue
Net income (quarterly)
-$202M -$101M $0 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
Net income

Reported EPS history

1–34 of 34
Q3 20262026-09-30-0.222026-11-0210-Q
Q2 20262026-06-30-0.252026-08-0510-Q
Q1 20262026-03-31-0.222026-05-0610-Q
Q4 2025 (derived)2025-12-31-0.172026-02-2510-K
FY 20252025-12-31-1.442026-02-2510-K
Q3 20252025-09-30-0.362025-11-0510-Q
Q2 20252025-06-30-0.412025-08-0510-Q
Q1 20252025-03-31-0.502025-05-0510-Q
Q4 2024 (derived)2024-12-31-0.562025-02-2810-K
FY 20242024-12-31-1.692025-02-2810-K
Q3 20242024-09-30-0.342024-11-0610-Q
Q2 20242024-06-30-0.402024-08-0810-Q
Q1 20242024-03-31-0.392024-05-0910-Q
Q4 2023 (derived)2023-12-31-0.432024-02-2910-K
FY 20232023-12-31-1.582024-02-2910-K
Q3 20232023-09-30-0.432023-11-0910-Q
Q2 20232023-06-30-0.382023-08-0810-Q
Q1 20232023-03-31-0.342023-05-0810-Q
Q4 2022 (derived)2022-12-31-0.302023-02-2710-K
FY 20222022-12-31-1.362023-02-2710-K
Q3 20222022-09-30-0.352022-11-0810-Q
Q2 20222022-06-30-0.382022-08-0910-Q
Q1 20222022-03-31-0.332022-05-1010-Q
Q4 2021 (derived)2021-12-310.432022-03-2310-K
FY 20212021-12-31-1.492022-03-2310-K
Q3 20212021-09-30-0.282021-11-1010-Q
Q2 20212021-06-30-0.312021-08-1310-Q
Q1 20212021-03-31-1.332021-05-1210-Q
Q4 2020 (derived)2020-12-31-1.17——
FY 20202020-12-31-3.99——
Q3 20202020-09-30-1.09——
Q2 20202020-06-30-0.88——
Q1 20202020-03-31-0.85——
FY 20192019-12-31-2.87——

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.